A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours

被引：0
|
作者：
Christophe Le Tourneau
Jean-Pierre Delord
Nuria Kotecki
Edith Borcoman
Carlos Gomez-Roca
Ségolène Hescot
Christiane Jungels
Anne Vincent-Salomon
Vincent Cockenpot
Lauriane Eberst
Audrey Molé
Wael Jdey
Françoise Bono
Véronique Trochon-Joseph
Hélène Toussaint
Christelle Zandanel
Olga Adamiec
Olivier de Beaumont
Philippe Alexandre Cassier
机构：
[1] Institut Curie,Department of Drug Development and Innovation (D3i)
[2] IUCT-Oncopole,Institut Claudius Régaud
[3] Institut Jules Bordet,Medical Oncology Clinic
[4] Institut Curie,Department of Tumor Biology
[5] Centre Léon Bérard,Medical Oncology
[6] Onxeo,Clinical Department
[7] Onxeo,Scientific Department
来源：
British Journal of Cancer | 2020年 / 123卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1481 / 1489
页数：8
相关论文
共 50 条
  • [21] First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours
    Schoeffski, Patrick
    Awada, Ahmad
    de la Bigne, Anne-Marie
    Felloussi, Zakia
    Burbridge, Mike
    Cantero, Frederique
    Colombo, Riccardo
    Maruzzelli, Sara
    Ammattatelli, Katia
    de Jonge, Maja
    Aftimos, Philippe
    Dumez, Herlinde
    Sleijfer, Stefan
    EUROPEAN JOURNAL OF CANCER, 2022, 169 : 135 - 145
  • [22] A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours
    Tolcher, A. W.
    Falchook, G.
    Bendell, J. C.
    Ungar, D.
    Boni, J.
    Chao, G.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 176 - +
  • [23] A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies
    Shapiro, Geoffrey I.
    Heath, Elizabeth
    Malburg, Lisa
    DeZube, Bruce
    Miles, Dale
    Keer, Harold N.
    Xu, Andrew X.
    Laeder, Theresa
    LoRusso, Patricia
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3510S - 3511S
  • [24] Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Jason D. Lickliter
    Mark Voskoboynik
    Linda Mileshkin
    Hui K. Gan
    Ganessan Kichenadasse
    Kathy Zhang
    Maggie Zhang
    Zhiyu Tang
    Michael Millward
    British Journal of Cancer, 2022, 126 : 310 - 310
  • [25] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Li, Xiaoyu
    Qiu, Meng
    Wang, ShengJun
    Zhu, Hong
    Feng, Bi
    Zheng, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 593 - 604
  • [26] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Xiaoyu Li
    Meng Qiu
    ShengJun Wang
    Hong Zhu
    Bi Feng
    Li Zheng
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 593 - 604
  • [27] A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Leong, Stephen
    Moss, Rebecca A.
    Bowles, Daniel W.
    Ware, Joseph A.
    Zhou, Jing
    Spoerke, Jill M.
    Lackner, Mark R.
    Shankar, Geetha
    Schutzman, Jennifer L.
    van der Noll, Ruud
    Voest, Emile E.
    Schellens, Jan H. M.
    ONCOLOGIST, 2017, 22 (12): : 1491 - 1499
  • [28] A PHASE 1/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Luke, Jason
    Janku, Filip
    Olszanski, Anthony
    Leach, Kevin
    Iyer, Radhakrishnan
    Abbas, Atif
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A224 - A224
  • [29] A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a novel cyclin-dependent kinase inhibitor administered weekly in subjects with advanced malignancies
    Bannerji, Rajat
    Saltzman, Marc
    Rosenberg, Mitchell A.
    Small, Karen
    Black, Stuart
    Kirschmeier, Paul
    Statkevich, Paul
    Abutarif, Malaz
    Parry, David
    Yao, Siu-Long
    Nernunaitis, John
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3372S - 3373S
  • [30] Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
    Champiat, Stephane
    Cassier, Philippe A.
    Kotecki, Nuria
    Korakis, Iphigenie
    Vinceneux, Armelle
    Jungels, Christiane
    Blatchford, Jon
    Elgadi, Mabrouk M.
    Clarke, Nicole
    Fromond, Claudia
    Poirier, Nicolas
    Vasseur, Berangere
    Marabelle, Aurelien
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345